Drugs / Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)
Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02888418 | Oct 2016 → Oct 2017 | cervical cancer | Beijing Chaoyang District Centre for Disease Control and Prevention | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02888418 ↗ |
| Modality | Vaccine | “Tetravalent recombinant human papilloma virus vaccine” NCT02888418 ↗ |